Extracellular Vesicles as Therapeutic Strategy for Ischemic Stroke

Area of Science:

• Neuroscience
• Regenerative Medicine
• Biotechnology

Background:

• Ischemic stroke is a major cause of death and disability globally.
• Current treatments for ischemic stroke have limitations, including narrow therapeutic windows and risk of hemorrhagic transformation.
• Extracellular vesicles (EVs) are emerging as a cell-free therapeutic strategy for ischemic stroke due to their regenerative and anti-inflammatory properties.

Purpose of the Study:

• To review recent advances in the application of EVs for ischemic stroke therapy.
• To highlight the mechanisms of action of EVs in promoting neuroprotection and regeneration.
• To summarize preclinical findings and discuss challenges for clinical translation.

Main Methods:

• Review of recent scientific literature on extracellular vesicles in ischemic stroke.
• Analysis of EV mechanisms, including cargo delivery (microRNAs, proteins) and effects on angiogenesis, neurogenesis, and apoptosis.
• Summary of preclinical data from various EV sources (mesenchymal stem cells, microglia, neural progenitor cells).
• Examination of bioengineered EVs for targeted delivery.

Main Results:

• EVs deliver neuroprotective molecules that promote angiogenesis, neurogenesis, and anti-apoptotic pathways.
• Preclinical studies demonstrate the regenerative potential of EVs from various cell types.
• Bioengineered EVs show promise for targeted delivery in ischemic stroke models.
• Challenges remain in large-scale production, content standardization, and efficient targeted delivery.

Conclusions:

• EVs represent a promising therapeutic avenue for ischemic stroke, offering a cell-free approach to modulate inflammation and enhance neuroregeneration.
• Optimizing EV characterization, manufacturing, and delivery systems is crucial for successful clinical translation.
• Future research should focus on addressing current limitations to ensure consistent efficacy and safety of EV-based therapies.